| 商品名称 | Infergen |
|---|---|
| 适用类别 | Human |
| 治疗领域 | Hepatitis C, Chronic |
| 通用名/非专利名称 | interferon alfacon-1 |
| 活性成分 | interferon alfacon-1 |
| 产品号 | EMEA/H/C/000186 |
| 患者安全信息 | No |
| 许可状态 | Withdrawn |
| ATC编码 | L03AB09 |
| 是否额外监管 | No |
| 是否仿制药或hybrid药物 | No |
| 是否生物类似药 | No |
| 是否附条件批准 | No |
| 是否特殊情形 | No |
| 是否加速审评 | No |
| 是否罕用药 | No |
| 上市许可日期 | 1999/02/01 |
| 上市许可开发者/申请人/持有人 | Astellas Pharma Europe B.V. |
| 人用药物治疗学分组 | Immunostimulants |
| 兽用药物治疗学分组 | |
| 欧盟委员会决定日期 | 2006/05/05 |
| 修订号 | 8 |
| 治疗适应症 | Treatment of patients of 18 years and older with chronic hepatitis and serum markers for hepatitis C virus (HCV) infection e.g. those who have elevated serum transaminase levels without decompensated liver disease and who are positive for serum HCV-RNA (see section 4.4). Consideration should be given to current official guidance on the appropriate use of interferons for the treatment of patients with chronic hepatitis C.Interferon alfacon-1 should be given alone mainly in case of intolerance or contraindication to ribavirin. |
| 适用物种 | |
| 兽用药物ATC编码 | |
| 首次发布日期 | 2006/05/05 |
| 最后更新日期 | 2006/06/01 |
| 产品说明书 | |
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/infergen |